FAS -670A>G promoter polymorphism is associated with soluble Fas levels in primary Sjögren's syndrome

Genetics and Molecular Research

Volumn 13, Issue 3, 2014, Pages 4831-4838

  Trevino Talavera B A ^a   Palafox Sanchez C A ^a,b   Munoz Valle J F ^a   Orozco Barocio, G ^b   Navarro Hernandez R E ^a   Mercado, M Vázquez Del ^a   Garcia de la Torre I ^b   Oregon Romero, E ^a  

^a UNIVERSITY OF GUADALAJARA   (Mexico)

^b Department of Rheumatology Western General Hospital   (Mexico)

Author keywords

FAS 670A>G polymorphism; FAS gene; Fas receptor; Primary Sj gren syndrome; Soluble Fas

Indexed keywords

FAS ANTIGEN; FAS RECEPTOR; MESSENGER RNA; SOLUBLE FAS PROTEIN; UNCLASSIFIED DRUG; FAS PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DNA ISOLATION; DNA POLYMORPHISM; ENZYME LINKED IMMUNOSORBENT ASSAY; ETHNICITY; GENE FREQUENCY; GENOTYPE; HETEROZYGOSITY; HUMAN; LABORATORY TEST; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MEXICAN; POLYMERASE CHAIN REACTION; PROMOTER REGION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SJOEGREN SYNDROME; ADULT; ALLELE; BIOLOGICAL MODEL; BLOOD; CASE CONTROL STUDY; FEMALE; GENE EXPRESSION; GENETIC POLYMORPHISM; GENETICS; HETEROZYGOTE; MALE; MIDDLE AGED; PATHOLOGY; SOLUBILITY;

ADULT; ALLELES; ANTIGENS, CD95; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENOTYPE; HETEROZYGOTE; HUMANS; MALE; MIDDLE AGED; MODELS, GENETIC; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; SJOGREN'S SYNDROME; SOLUBILITY;

EID: 84903976156     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/2014.July.2.12     Document Type: Article

References (20)

1. Agarwal K, Czaja AJ and Donaldson PT (2007). A functional Fas promoter polymorphism is associated with a severe phenotype in type 1 autoimmune hepatitis characterized by early development of cirrhosis. Tissue Antigens 69: 227-235.
2. Arasteh JM, Sarvestani EK, Aflaki E and Amirghofran Z (2010). Fas gene polymorphisms in systemic lupus erythematosus and serum levels of some apoptosis-related molecules. Immunol. Invest. 39: 27-38.
3. Ates A, Kinikli G, Turgay M and Duman M (2004). The levels of serum-soluble Fas in patients with rheumatoid arthritis and systemic sclerosis. Clin. Rheumatol. 23: 421-425.
4. Bolstad AI, Eiken HG, Rosenlund B, Alarcon-Riquelme ME, et al. (2003). Increased salivary gland tissue expression of Fas, Fas ligand, cytotoxic T lymphocyte-associated antigen 4, and programmed cell death 1 in primary Sjögren's syndrome. Arthritis Rheum. 48: 174-185.
5. Cheng J, Zhou T, Liu C, Shapiro JP, et al. (1994). Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 263: 1759-1762.
6. Hao JH, Ye DQ, Zhang GQ, Liu HH, et al. (2006). Elevated levels of serum soluble Fas are associated with organ and tissue damage in systemic lupus erythematosus among Chinese. Arch. Dermatol. Res. 297: 329-332.
7. Hiraide A, Imazeki F, Yokosuka O, Kanda T, et al. (2005). Fas polymorphisms influence susceptibility to autoimmune hepatitis. Am. J. Gastroenterol. 100: 1322-1329.
8. Hondowicz BD, Fields ML, Nish SA, Larkin J, et al. (2008). Autoantibody production in lpr/lpr gld/gld mice reflects accumulation of CD4+ effector cells that are resistant to regulatory T cell activity. J. Autoimmun. 31: 98-109.
9. Kanemitsu S, Ihara K, Saifddin A, Otsuka T, et al. (2002). A functional polymorphism in fas (CD95/APO-1) gene promoter associated with systemic lupus erythematosus. J. Rheumatol. 29: 1183-1188.
10. Mahfoudh W, Bel H Jr, Romdhane A and Chouchane L (2007). A polymorphism in FAS gene promoter correlated with circulating soluble FAS levels. Int. J. Immunogenet. 34: 209-212.
11. Mavragani CP and Moutsopoulos HM (2010). The geoepidemiology of Sjögren's syndrome. Autoimmun. Rev. 9: A305-A310.
12. Miller SA, Dykes DD and Polesky HF (1988). A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 16: 1215.
13. Mullighan CG, Heatley S, Lester S, Rischmueller M, et al. (2004). Fas gene promoter polymorphisms in primary Sjögren's syndrome. Ann. Rheum. Dis. 63: 98-101.
14. Niemela JE, Hsu AP, Fleisher TA and Puck JM (2006). Single nucleotide polymorphisms in the apoptosis receptor gene TNFRSF6. Mol. Cell Probes 20: 21-26.
15. Niino M, Kikuchi S, Fukazawa T, Miyagishi R, et al. (2002). An examination of the Apo-1/Fas promoter Mva I polymorphism in Japanese patients with multiple sclerosis. BMC Neurol. 2: 8.
16. Ohlsson M, Skarstein K, Bolstad AI, Johannessen AC, et al. (2001). Fas-induced apoptosis is a rare event in Sjögren's syndrome. Lab. Invest. 81: 95-105.
17. Ohlsson M, Jonsson R and Brokstad KA (2002). Subcellular redistribution and surface exposure of the Ro52, Ro60 and La48 autoantigens during apoptosis in human ductal epithelial cells: a possible mechanism in the pathogenesis of Sjögren's syndrome. Scand. J. Immunol. 56: 456-469.
18. Sun T, Miao X, Zhang X, Tan W, et al. (2004). Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J. Natl. Cancer Inst. 96: 1030-1036.
19. van Veen T, Kalkers NF, Crusius JB, van Winsen L, et al. (2002). The FAS-670 polymorphism influences susceptibility to multiple sclerosis. J. Neuroimmunol. 128: 95-100.
20. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, et al. (2002). Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann. Rheum. Dis. 61: 554-558.